These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 16023806)

  • 21. Assessment of the need to coat particle collection cups of the NGI to mitigate droplet bounce when evaluating nebuliser-produced droplets.
    Berg E; Lamb P; Ali A; Dennis J; Tservistas M; Mitchell J
    Pharmeur Sci Notes; 2008 Feb; 2008(1):21-5. PubMed ID: 18430403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of a double-layered ceramic filter for aerosol filtration at high-temperatures: the filter collection efficiency.
    de Freitas NL; Gonçalves JA; Innocentini MD; Coury JR
    J Hazard Mater; 2006 Aug; 136(3):747-56. PubMed ID: 16466854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cascade impactor practice for a high dose dry powder inhaler at 90 L/min: NGI versus modified 6-stage and 8-stage ACI.
    Kamiya A; Sakagami M; Byron PR
    J Pharm Sci; 2009 Mar; 98(3):1028-39. PubMed ID: 18661538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physical characteristics and aerosol performance of naringin dry powders for pulmonary delivery prepared by spray-drying.
    Sansone F; Aquino RP; Del Gaudio P; Colombo P; Russo P
    Eur J Pharm Biopharm; 2009 May; 72(1):206-13. PubMed ID: 18996478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medical nebulizer performance: effects of cascade impactor temperature.
    Zhou Y; Ahuja A; Irvin CM; Kracko DA; McDonald JD; Cheng YS
    Respir Care; 2005 Aug; 50(8):1077-82. PubMed ID: 16225713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Size-separated sampling and analysis of isocyanates in workplace aerosols. Part I. Denuder--cascade impactor sampler.
    Dahlin J; Spanne M; Karlsson D; Dalene M; Skarping G
    Ann Occup Hyg; 2008 Jul; 52(5):361-74. PubMed ID: 18458354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and Validation of a High-Volume, Low-Cutoff Inertial Impactor.
    Kavouras IG; Ferguson ST; Wolfson JM; Koutrakis P
    Inhal Toxicol; 2000 Jan; 12 Suppl 2():35-50. PubMed ID: 26368520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of highly porous large PLGA microparticles for pulmonary drug delivery.
    Yang Y; Bajaj N; Xu P; Ohn K; Tsifansky MD; Yeo Y
    Biomaterials; 2009 Apr; 30(10):1947-53. PubMed ID: 19135245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlations between cascade impactor analysis and laser diffraction techniques for the determination of the particle size of aerosolised powder formulations.
    Pilcer G; Vanderbist F; Amighi K
    Int J Pharm; 2008 Jun; 358(1-2):75-81. PubMed ID: 18359587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of nonideal cascade impactor stage collection efficiency curves on the interpretation of the size of inhaler-generated aerosols.
    Roberts DL; Mitchell JP
    AAPS PharmSciTech; 2013 Jun; 14(2):497-510. PubMed ID: 23508617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effective dose scaling factors for use with uranium series cascade impactor data: a reassessment using the IMBA code.
    Kim KP; Wu CY; Birky BK; Bolch WE
    Health Phys; 2006 Oct; 91(4):331-7. PubMed ID: 16966876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of preseparator performance for the 8-stage nonviable andersen impactor.
    Sethuraman VV; Hickey AJ
    AAPS PharmSciTech; 2001 Mar; 2(1):E4. PubMed ID: 14727889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhalable microparticles containing large payload of anti-tuberculosis drugs.
    Muttil P; Kaur J; Kumar K; Yadav AB; Sharma R; Misra A
    Eur J Pharm Sci; 2007 Oct; 32(2):140-50. PubMed ID: 17681458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new particle size analyzer.
    Abedini E; Tabrizchi M
    Rev Sci Instrum; 2009 Dec; 80(12):123303. PubMed ID: 20059136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients.
    Minne A; Boireau H; Horta MJ; Vanbever R
    Eur J Pharm Biopharm; 2008 Nov; 70(3):839-44. PubMed ID: 18620052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and laboratory performance evaluation of a personal cascade impactor.
    Demokritou P; Gupta T; Ferguson S; Koutrakis P
    J Air Waste Manag Assoc; 2002 Oct; 52(10):1230-7. PubMed ID: 12418733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Physicochemical characterization of Capstone depleted uranium aerosols II: particle size distributions as a function of time.
    Cheng YS; Kenoyer JL; Guilmette RA; Parkhurst MA
    Health Phys; 2009 Mar; 96(3):266-75. PubMed ID: 19204485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancing bioaerosol sampling by Andersen impactors using mineral-oil-spread agar plate.
    Xu Z; Wei K; Wu Y; Shen F; Chen Q; Li M; Yao M
    PLoS One; 2013; 8(2):e56896. PubMed ID: 23460818
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization and aerodynamic evaluation of spray dried recombinant human growth hormone using protein stabilizing agents.
    Jalalipour M; Gilani K; Tajerzadeh H; Najafabadi AR; Barghi M
    Int J Pharm; 2008 Mar; 352(1-2):209-16. PubMed ID: 18164150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved quality control metrics for cascade impaction measurements of orally inhaled drug products (OIPs).
    Tougas TP; Christopher D; Mitchell JP; Strickland H; Wyka B; Van Oort M; Lyapustina S
    AAPS PharmSciTech; 2009; 10(4):1276-85. PubMed ID: 19882251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.